Company Overview of Cytos Biotechnology AG
As of January 20, 2016, Cytos Biotechnology AG was acquired by Kuros Biosurgery AG, in a reverse merger transaction. Cytos Biotechnology AG focuses on the development and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases. The company has collaborative research, option, and license agreement with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; license agreement with Pfizer Inc. for developing an anti-IgE vaccine; and collaborative research, development, and commercialization agreement with Singapore’s Agency for Science, Technology and Research. Cytos Biotechnology...
Key Executives for Cytos Biotechnology AG
Cytos Biotechnology AG does not have any Key Executives recorded.
Cytos Biotechnology AG Key Developments
Cytos Biotechnology AG has Changed its Ticker to KURN from CYTN
Jan 20 16
Effective January 20, 2016, Cytos Biotechnology AG changed its SIX Swiss Exchange stock ticker symbol to KURN from CYTN.
Cytos Biotechnology Ltd. Announces Management Changes
Jan 8 16
Cytos Biotechnology Ltd. announced that the board of directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as chairman of the board and Mr. Dominik Ellenrieder being appointed as the vice chairman of the board. Further, the newly constituted board elected Didier Cowling as chief executive officer, Dr. Alistair Irvine as chief business officer, Dr. Jason Schense as chief technology officer and confirmed Harry Welten as the chief financial officer. All appointments are effective upon closing of the acquisition of Kuros Biosurgery Holding AG which is expected to take place within the next few weeks.
Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Jan 06, 2016
Dec 15 15
Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Jan 06, 2016, at 10:30 Central European Standard Time. Agenda: To approve the transaction with Kuros Biosurgery Holding AG.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 3, 2015
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries